118 related articles for article (PubMed ID: 26660762)
1. Structural Insights into the Pharmacophore of Vinca Domain Inhibitors of Microtubules.
Wang Y; Benz FW; Wu Y; Wang Q; Chen Y; Chen X; Li H; Zhang Y; Zhang R; Yang J
Mol Pharmacol; 2016 Feb; 89(2):233-42. PubMed ID: 26660762
[TBL] [Abstract][Full Text] [Related]
2. Microtubule and tubulin binding and regulation of microtubule dynamics by the antibody drug conjugate (ADC) payload, monomethyl auristatin E (MMAE): Mechanistic insights into MMAE ADC peripheral neuropathy.
Best RL; LaPointe NE; Azarenko O; Miller H; Genualdi C; Chih S; Shen BQ; Jordan MA; Wilson L; Feinstein SC; Stagg NJ
Toxicol Appl Pharmacol; 2021 Jun; 421():115534. PubMed ID: 33852878
[TBL] [Abstract][Full Text] [Related]
3. Structural Basis of Microtubule Destabilization by Potent Auristatin Anti-Mitotics.
Waight AB; Bargsten K; Doronina S; Steinmetz MO; Sussman D; Prota AE
PLoS One; 2016; 11(8):e0160890. PubMed ID: 27518442
[TBL] [Abstract][Full Text] [Related]
4. The high-resolution X-ray structure of vinca-domain inhibitors of microtubules provides a rational approach for drug design.
Chengyong W; Jinghong X; Yanyan W; Qing-Jie X; Lingling M; Yuyan L; Hai C; Qian L; Quan Z; Bo S; Yuxi W
FEBS Lett; 2021 Jan; 595(2):195-205. PubMed ID: 33220079
[TBL] [Abstract][Full Text] [Related]
5. Theoretical insight into the structural mechanism for the binding of vinblastine with tubulin.
Chi S; Xie W; Zhang J; Xu S
J Biomol Struct Dyn; 2015; 33(10):2234-54. PubMed ID: 25588192
[TBL] [Abstract][Full Text] [Related]
6. A new tubulin-binding site and pharmacophore for microtubule-destabilizing anticancer drugs.
Prota AE; Bargsten K; Diaz JF; Marsh M; Cuevas C; Liniger M; Neuhaus C; Andreu JM; Altmann KH; Steinmetz MO
Proc Natl Acad Sci U S A; 2014 Sep; 111(38):13817-21. PubMed ID: 25114240
[TBL] [Abstract][Full Text] [Related]
7. Structural plasticity of tubulin assembly probed by vinca-domain ligands.
Ranaivoson FM; Gigant B; Berritt S; Joullié M; Knossow M
Acta Crystallogr D Biol Crystallogr; 2012 Aug; 68(Pt 8):927-34. PubMed ID: 22868758
[TBL] [Abstract][Full Text] [Related]
8. Structural comparison of the interaction of tubulin with various ligands affecting microtubule dynamics.
Stec-Martyna E; Ponassi M; Miele M; Parodi S; Felli L; Rosano C
Curr Cancer Drug Targets; 2012 Jul; 12(6):658-66. PubMed ID: 22385515
[TBL] [Abstract][Full Text] [Related]
9. The Unique Binding Mode of Laulimalide to Two Tubulin Protofilaments.
Churchill CD; Klobukowski M; Tuszynski JA
Chem Biol Drug Des; 2015 Aug; 86(2):190-9. PubMed ID: 25376845
[TBL] [Abstract][Full Text] [Related]
10. The X-ray structure of tubulysin analogue TGL in complex with tubulin and three possible routes for the development of next-generation tubulysin analogues.
Li W; Tan L; Zhang Z; Xia Q; Lei D; Li Y; Zhang T; Zeng S; Sima X; Wang Y
Biochem Biophys Res Commun; 2021 Aug; 565():29-35. PubMed ID: 34090207
[TBL] [Abstract][Full Text] [Related]
11. Structural insight into the inhibition of tubulin by vinca domain peptide ligands.
Cormier A; Marchand M; Ravelli RB; Knossow M; Gigant B
EMBO Rep; 2008 Nov; 9(11):1101-6. PubMed ID: 18787557
[TBL] [Abstract][Full Text] [Related]
12. Absolute configurations of tubulin inhibitors taltobulin (HTI-286) and HTI-042 characterized by X-ray diffraction analysis and NMR studies.
Niu C; Ho DM; Williamson RT; Zask A; Ayral-Kaloustian S
Bioorg Med Chem Lett; 2010 Mar; 20(5):1535-8. PubMed ID: 20137930
[TBL] [Abstract][Full Text] [Related]
13. Tubulin inhibitors: a patent review.
Liu YM; Chen HL; Lee HY; Liou JP
Expert Opin Ther Pat; 2014 Jan; 24(1):69-88. PubMed ID: 24313741
[TBL] [Abstract][Full Text] [Related]
14. Cyclostreptin binds covalently to microtubule pores and lumenal taxoid binding sites.
Buey RM; Calvo E; Barasoain I; Pineda O; Edler MC; Matesanz R; Cerezo G; Vanderwal CD; Day BW; Sorensen EJ; López JA; Andreu JM; Hamel E; Díaz JF
Nat Chem Biol; 2007 Feb; 3(2):117-25. PubMed ID: 17206139
[TBL] [Abstract][Full Text] [Related]
15. Insights into the interaction of discodermolide and docetaxel with tubulin. Mapping the binding sites of microtubule-stabilizing agents by using an integrated NMR and computational approach.
Canales A; Rodríguez-Salarichs J; Trigili C; Nieto L; Coderch C; Andreu JM; Paterson I; Jiménez-Barbero J; Díaz JF
ACS Chem Biol; 2011 Aug; 6(8):789-99. PubMed ID: 21539341
[TBL] [Abstract][Full Text] [Related]
16. Structural convergence for tubulin binding of CPAP and vinca domain microtubule inhibitors.
Campanacci V; Urvoas A; Ammar Khodja L; Aumont-Nicaise M; Noiray M; Lachkar S; Curmi PA; Minard P; Gigant B
Proc Natl Acad Sci U S A; 2022 May; 119(19):e2120098119. PubMed ID: 35507869
[TBL] [Abstract][Full Text] [Related]
17. The Mechanism of the Interactions of Pironetin Analog/Combretastatin A-4 Hybrids with Tubulin.
Torijano-Gutiérrez S; Vilanova C; Díaz-Oltra S; Murga J; Falomir E; Carda M; Redondo-Horcajo M; Díaz JF; Barasoain I; Marco JA
Arch Pharm (Weinheim); 2015 Aug; 348(8):541-7. PubMed ID: 26085125
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and biological evaluation of vinca alkaloids and phomopsin hybrids.
Ngo QA; Roussi F; Cormier A; Thoret S; Knossow M; Guénard D; Guéritte F
J Med Chem; 2009 Jan; 52(1):134-42. PubMed ID: 19072542
[TBL] [Abstract][Full Text] [Related]
19. Microtubules dual chemo and thermo-responsive depolymerization.
Li Z; Alisaraie L
Proteins; 2015 May; 83(5):970-81. PubMed ID: 25739855
[TBL] [Abstract][Full Text] [Related]
20. Tumor cells resistant to a microtubule-depolymerizing hemiasterlin analogue, HTI-286, have mutations in alpha- or beta-tubulin and increased microtubule stability.
Poruchynsky MS; Kim JH; Nogales E; Annable T; Loganzo F; Greenberger LM; Sackett DL; Fojo T
Biochemistry; 2004 Nov; 43(44):13944-54. PubMed ID: 15518543
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
